Integrated DNA Technologies (IDT) has launched the first next generation sequencing product for cancer. The xGen Acute Myeloid Leukaemia Cancer Panel has 11,743 xGen Lockdown Probes that has the capacity of targeting more than 260 genes whose mutations are found to be closely associated with 200 patients with acute myeloid leukaemia.
The AML Cancer Panel can be used to enrich regions of interest in the genome, making it instrumental in the study of disease occurrence and progression. With xGen AML Cancer Panel targeting relevant genes, it reduces the cost and time otherwise required to sequence the whole genome. The cancer profile of a patient can be easily constructed by enriching their DNA and identifying the mutated genes using IDT’s xGen AML Cancer Panel and treating the condition accordingly. The progress of disease and treatment can also be monitored by periodic sequencing.
The introduction of xGen Acute Myeloid Leukaemia Cancer Panel allows oncologists to detect and decide up on tailored therapies for patients, offering personalized treatment quicker and cheaper than before.
Source: Integrated DNA Technologies